RxDoctor Payments Data

Ashley Carlile, NP

Family · Rome, GANPI 1952615031

Payments from drug & device makers

$6,426in general payments, 2019–2025

Across 213 payments — averaging $30.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Abbott$468
  • Collegium Pharmaceutical, Inc.$396
  • Biotronik NRO, Inc.$375
  • Nevro Corp.$333
  • Forte Bio-pharma LLC$270
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$6,426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,426 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$9,573
Medicare patients
55
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl19$12,800
Buprenorphine36$9,272
Pregabalin174$4,495
Gabapentin201$2,842
Lubiprostone23$1,977
Diclofenac Sodium26$1,762
Cyclobenzaprine Hcl110$872
Tramadol Hcl110$778
Methocarbamol67$738
Tizanidine Hcl81$556
Duloxetine Hcl56$539
Acetaminophen-CodeineAcetaminophen With Codeine28$338
Eszopiclone14$330
Baclofen26$274
Celecoxib11$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$396$12,80019 claims
Hikma Pharmaceuticals USABuprenorphine$14$9,27236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →